SCHEMBL5548035

SCHEMBL5548035

Cc1nc(-c2ccccc2F)c(C)o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MBNL1 Q9NR56 1/20 0.47
MAPT P10636 3/20 0.43
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
GAA P10253 1/20 0.42
PTGS1 P23219 1/20 0.42
MEN1 O00255 2/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
KMT2A Q03164 2/20 0.41
RELA Q04206 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ADORA2A P29274 1/20 0.40
F2 P00734 1/20 0.38
KDM4E B2RXH2 2/20 0.38
C1R P00736 1/20 0.38
DPP4 P27487 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5548033 0.82 MBNL1 (0.45) MBNL1MAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL3826939 0.78 DPP4 (0.43) MBNL1MAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL5541542 0.78 MAPT (0.49) MAPTALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL10832913 0.77 HSD11B1 (0.47) MAPTALDH1A1NPC1L3MBTL1C1R
SCHEMBL20027762 0.77 MAPT (0.47) MBNL1MAPTALDH1A1SMN1; SMN2NPC1
Hydrochloric Acid SCHEMBL3822585 0.77 DPP4 (0.42) MBNL1MAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL3826937 0.76 NPC1 (0.44) MBNL1MAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL10263295 0.74 NPC1 (0.42) MBNL1MAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL29691084 0.74 TSHR (0.41) MAPTALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL5214925 0.72 MAPK13 (0.58) MAPTALDH1A1SMN1; SMN2RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MBNL1 2669/4885MAPT 4117/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.